TG Therapeutics (NASDAQ: TGTX) files 8-K on Q3 2025 results

Rhea-AI Filing Summary

TG Therapeutics, Inc. filed a current report to note that it has released its financial results. On November 3, 2025, the company issued a press release covering its results of operations for the three and nine months ended September 30, 2025, and furnished that release as Exhibit 99.1. The information about these quarterly and year-to-date results is being furnished, not filed, which means it is not automatically subject to certain liability provisions or incorporated into other SEC filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001001316 0001001316 2025-11-03 2025-11-03

 ​​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 3, 2025

TG Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-32639	36-3898269
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer Identification No.)
of Incorporation)	​	​

 ​

3020 Carrington Mill Blvd, Suite 475

Morrisville, North Carolina 27560

(Address of Principal Executive Offices)

(212) 554-4484

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities filed pursuant to Section 12(b) of the Act:

Title of Class	Trading Symbol(s)	Exchange Name
Common Stock	TGTX	Nasdaq Capital Market

 ​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

 ​

On November 3, 2025, the Company issued a press release announcing results of operations for the three and nine months ended September 30, 2025. A copy of such press release is being furnished as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by TG Therapeutics, Inc., dated November 3, 2025.
104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL.

 ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	TG Therapeutics, Inc.
​	(Registrant)
Date: November 3, 2025	By:	/s/ Sean A. Power
​	​	Sean A. Power
​	​	Chief Financial Officer

 ​

FAQ

What did TG Therapeutics (TGTX) report in this 8-K filing?

The company reported that it issued a press release on November 3, 2025 announcing its results of operations for the three and nine months ended September 30, 2025, and furnished that release as Exhibit 99.1.

Which financial periods are covered by TG Therapeutics' November 3, 2025 press release?

The press release covers TG Therapeutics’ results of operations for the three-month and nine-month periods ended September 30, 2025.

How is the TG Therapeutics (TGTX) earnings information treated for SEC purposes?

The information in Item 2.02, including Exhibit 99.1, is being furnished rather than filed, so it is not deemed subject to Section 18 of the Exchange Act or automatically incorporated into other SEC filings unless specifically referenced.

What exhibit is included with this TG Therapeutics Form 8-K?

Exhibit 99.1 is the press release issued by TG Therapeutics, Inc. dated November 3, 2025, and Exhibit 104 is the cover page formatted in Inline XBRL.

Who signed the TG Therapeutics November 3, 2025 Form 8-K?

The report was signed on behalf of TG Therapeutics, Inc. by Sean A. Power, the company’s Chief Financial Officer.

On which exchange is TG Therapeutics (TGTX) common stock listed?

TG Therapeutics’ common stock, trading under the symbol TGTX, is listed on the Nasdaq Capital Market.